As US medtech heavyweights pour billions into bladder-control therapies for ageing populations, an Australian company is ...
SPR will feature eight abstracts on 60-day peripheral nerve stimulation (PNS) with SPRINT® PNS that will be presented at the ...
In severe treatment-resistant depression, long-term data show VNS benefits not only persist for 2 years but also continue to emerge in late responders.
Phagenesis, a commercial-stage company with a first-of-its-kind neuromodulation system to treat patients experiencing difficulty swallowing post-stroke, welcomed the 2026 Guideline for the Early ...
Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results